OBJECTIVES: Selective serotonin reuptake inhibitors (SSRIs) have been associated with increased risk of osteoporotic-related fractures. Bisphosphonates (BPs) are one of the recommended medications for osteoporosis and fracture prevention. The primary objective of this study was to examine the proportion of BP users who are also on SSRIs and to explore the relationship between concomitant use and patient age among women aged 45 years and older. METHODS: Data from the 2004-2008 Medical Expenditure Panel Survey (MEPS) was used to examine usage patterns of BPs and SSRIs for women aged ≥45 years. Analyses were based on yearly consolidated data and prescribed medicines files. Weighed descriptive statistics were used to evaluate patterns of medications use and proportions were reported. Age was categorized into two groups: 45-64, and 65-85 years old. RESULTS: In the timeframe examined, 3.5% women in 2004, 3.8% in 2005, 4.0% in 2006, 3.9% in 2007, and 4.0% in 2008 received bisphosphonates. In the same period, 8.6% women in 2004, 8.5% in 2005, 8.1% in 2006, 7.4% in 2007, and 7.9% in 2008 received SSRIs. Concomitant use (BPs+SSRIs) was observed in 0.4% women in 2004, 0.5% in 2005, 0.6% in 2006, 0.6% in 2007, and 0.6% in 2008. In 2006, 2007, and 2008, concomitant use of BPs+SSRIs was higher in the 65-85 age group compared to that of 45-64 years. This pattern may be in large part due to increasing population of older women in the United States. CONCLUSIONS: Concomitant use of BPs and SSRIs in adult women ≥45 years is not uncommon and might be higher in older postmenopausal women. The observed concomitant use presents drug safety challenges surrounding the bone health of postmenopausal women. Studies are needed to investigate the potential interactive effects of SSRIs on BP therapy.